Incyte Corp. Share Price
NASDAQ: INCY | Large CapIncyte Corp. Stock Performance
Incyte Corp. Share Price Today
As of 30 October 2026, Incyte Corp.'s share price is $116.79. The stock opened at $111.43, compared to its previous close of $116.81. During today's trading session, Incyte Corp.'s share price traded between $111.43 and $117.06, with an average price of $114.24. Over the past 52 weeks, the stock has recorded a high of $132.59 and a low of $88.39. In terms of performance, Incyte Corp.'s share price has risen by 22.44% over the last six months and is up 24.95% on a year-on-year basis.
Incyte Corp. Share Price Chart
Incyte Corp. Quarterly Profit & Loss
All figures in USD
Incyte Corp. Annual Profit & Loss
All figures in USD
About Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Incyte Corp. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $121.15 | $116.79 | -3.83% |
Sep 2026 | $125.08 | $121.44 | -4.92% |
Aug 2026 | $120.49 | $127.72 | +6.91% |
Jul 2026 | $114.70 | $119.47 | +5.44% |
Jun 2026 | $96.33 | $113.31 | +17.20% |
May 2026 | $95.22 | $96.68 | +1.36% |
Apr 2026 | $94.75 | $95.39 | +1.34% |
Mar 2026 | $99.91 | $94.13 | -7.01% |
Feb 2026 | $99.55 | $101.22 | +1.20% |
Jan 2026 | $98.51 | $100.02 | +1.25% |
Dec 2025 | $103.62 | $98.79 | -5.46% |
Nov 2025 | $93.95 | $104.50 | +11.80% |